Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“pCR rates of 55 – 57% with perioperative EV + pembrolizumab in MIBC are real.
But clinical complete response is not a reliable surrogate for pathologic clearance. 52% of patients with endoscopic cCR still harbor residual tumor at cystectomy.
ctDNA misses up to 1 in 5 cases of residual disease. Bladder preservation is achievable in selected patients – but rigorous prospective validation is still needed before deferring cystectomy.”
Title: AUA2026 PLENARY RECAP Bladder Preservation After Neoadjuvant Chemotherapy: Stick to the Plan!
Authors: Ashish M. Kamat, Amy N. Luckenbaugh, Alejandro Rodriguez
You can also read:
María Natalia GaNdur Quiroga: KEYNOTE-B15 Advances Perioperative Treatment in MIBC
